# Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.

> **NCT03843905** · — · UNKNOWN · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 300 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Microbiota
- Prognosis
- Metabolic Syndrome
- Sarcopenia

## Interventions

- **OTHER:** no intervention

## Key facts

- **NCT ID:** NCT03843905
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-15
- **Primary completion:** 2018-11-15
- **Final completion:** 2021-11-15
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843905, "Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03843905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*